JPMorgan Chase & Co. Raises Stock Holdings in Definitive Healthcare Corp. (NASDAQ:DH)

JPMorgan Chase & Co. increased its position in Definitive Healthcare Corp. (NASDAQ:DH - Free Report) by 49.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 331,264 shares of the company's stock after buying an additional 109,174 shares during the period. JPMorgan Chase & Co. owned 0.29% of Definitive Healthcare worth $1,361,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. 272 Capital LP raised its position in shares of Definitive Healthcare by 74.8% during the 3rd quarter. 272 Capital LP now owns 1,114,080 shares of the company's stock valued at $4,980,000 after buying an additional 476,766 shares in the last quarter. State Street Corp increased its stake in Definitive Healthcare by 29.4% during the third quarter. State Street Corp now owns 1,399,729 shares of the company's stock worth $6,257,000 after acquiring an additional 317,952 shares during the last quarter. PNC Financial Services Group Inc. raised its position in Definitive Healthcare by 928.3% during the fourth quarter. PNC Financial Services Group Inc. now owns 156,997 shares of the company's stock valued at $645,000 after purchasing an additional 141,729 shares during the period. Barclays PLC lifted its stake in shares of Definitive Healthcare by 318.8% in the 3rd quarter. Barclays PLC now owns 81,916 shares of the company's stock valued at $366,000 after purchasing an additional 62,354 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Definitive Healthcare by 35.9% in the 4th quarter. Bank of New York Mellon Corp now owns 229,143 shares of the company's stock worth $942,000 after purchasing an additional 60,559 shares during the period. 98.67% of the stock is owned by institutional investors.

Analysts Set New Price Targets

DH has been the subject of a number of analyst reports. Barclays lowered their price target on Definitive Healthcare from $4.00 to $3.00 and set an "underweight" rating for the company in a research report on Monday, March 3rd. The Goldman Sachs Group lowered their target price on shares of Definitive Healthcare from $4.50 to $3.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Definitive Healthcare in a report on Thursday, January 16th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $5.35.

Definitive Healthcare Trading Up 2.2 %

Shares of Definitive Healthcare stock traded up $0.06 on Tuesday, hitting $2.77. 520,570 shares of the company traded hands, compared to its average volume of 850,161. Definitive Healthcare Corp. has a 52 week low of $2.15 and a 52 week high of $7.47. The company has a market cap of $312.76 million, a PE ratio of -0.89, a PEG ratio of 4.06 and a beta of 1.48. The stock's 50 day moving average price is $2.97 and its 200-day moving average price is $3.97. The company has a current ratio of 2.49, a quick ratio of 2.49 and a debt-to-equity ratio of 0.33.

Definitive Healthcare (NASDAQ:DH - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.04). The firm had revenue of $62.29 million during the quarter, compared to analysts' expectations of $60.60 million. Definitive Healthcare had a positive return on equity of 1.76% and a negative net margin of 142.38%. Equities research analysts predict that Definitive Healthcare Corp. will post 0.16 EPS for the current year.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.